Daniel Menichella has been named chief executive of CureVac AG, effective 20 June, to succeed the company’s founder and CEO Ingmar Hoerr. Dr Hoerr is to move to the supervisory board and subsequently stand for election as chairman.
The management changes come as the company accelerates development of its candidate products for cancer and infectious disease using mRNA technology. Mr Menichella joined CureVac in early 2017. As a member of the executive committee, he served as head of the company’s US subsidiary as well as directed global business development.
CureVac AG announced the appointment on 8 May 2018.
Copyright 2018 Evernow Publishing Ltd